!%Invitrogen Corp.%! of Carlsbad, Calif., will acquire Phillipsburg, New Jersey-based Sentigen Holding Corp., a developer of bioassay systems, in a cash transaction valued at $3.37 a share, or approximately $25.9 million. With the purchase, the California company will expand its cellular assay capabilities.